Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsShares IssuedShares OutstandingShares RepurchasedWages, Salaries and Other
Ratios

BridgeBio Pharma (BBIO) Long-Term Debt Issuances (2019 - 2025)

Historic Long-Term Debt Issuances for BridgeBio Pharma (BBIO) over the last 5 years, with Q1 2025 value amounting to $575.0 million.

  • BridgeBio Pharma's Long-Term Debt Issuances rose 2777.78% to $575.0 million in Q1 2025 from the same period last year, while for Sep 2025 it was $575.0 million, marking a year-over-year increase of 2777.78%. This contributed to the annual value of $450.0 million for FY2024, which is N/A changed from last year.
  • Per BridgeBio Pharma's latest filing, its Long-Term Debt Issuances stood at $575.0 million for Q1 2025, which was up 2777.78% from $450.0 million recorded in Q1 2024.
  • BridgeBio Pharma's Long-Term Debt Issuances' 5-year high stood at $747.5 million during Q1 2021, with a 5-year trough of $450.0 million in Q1 2024.
  • In the last 3 years, BridgeBio Pharma's Long-Term Debt Issuances had a median value of $575.0 million in 2025 and averaged $590.8 million.
  • Per our database at Business Quant, BridgeBio Pharma's Long-Term Debt Issuances skyrocketed by 3590.91% in 2021 and then surged by 2777.78% in 2025.
  • Over the past 3 years, BridgeBio Pharma's Long-Term Debt Issuances (Quarter) stood at $747.5 million in 2021, then tumbled by 39.8% to $450.0 million in 2024, then increased by 27.78% to $575.0 million in 2025.
  • Its Long-Term Debt Issuances was $575.0 million in Q1 2025, compared to $450.0 million in Q1 2024 and $747.5 million in Q1 2021.